We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Autologous Dendritic Cell Vaccine in HIV1 Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00510497
Recruitment Status : Completed
First Posted : August 2, 2007
Results First Posted : April 4, 2016
Last Update Posted : June 16, 2016
Information provided by (Responsible Party):

August 1, 2007
August 2, 2007
January 12, 2016
April 4, 2016
June 16, 2016
July 2007
September 2012   (Final data collection date for primary outcome measure)
Safety and Tolerability of Autologous HIV-1 ApB DC Vaccine. [ Time Frame: 80 weeks ]
AE graded by Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, version 1.0, December 2004
The primary endpoint is the safety and tolerability of autologous HIV-1 ApB DC Vaccine. [ Time Frame: 80 weeks ]
Complete list of historical versions of study NCT00510497 on ClinicalTrials.gov Archive Site
Virologic Efficacy (HIV-1 Viral Load at End of ATI Minus Viral Load Prior to ART) [ Time Frame: at the end of 12 weeks treatment interruption ]
Log10 Change in HIV RNA set point comparing pre-ART to 12 weeks after treatment interruption
Virologic efficacy (HIV-1 viral load at end of ATI minus viral load prior to ART) and immunologic response (number of T cells reactive against the vaccine as measured by both ELISPOT assay, ICC Staining, and lymphocyte proliferation assay by CFSE) [ Time Frame: at the end of 12 weeks treatment interruption ]
Not Provided
Not Provided
Autologous Dendritic Cell Vaccine in HIV1 Infection
Phase I/II Evaluation of Therapeutic Immunization With Autologous Dendritic Cells Pulsed With Autologous, Inactivated HIV-1 Infected, Apoptotic Cells
This study aims to look at the safety and tolerability of immunization with dendritic cell vaccine prepared using the patient's own cells and virus. It also aims to explore the virologic efficacy of the vaccine as determined by a decrease in the viral load 12 weeks after analytic treatment interruption.
This is a phase I/II, open label, single-arm, single-site clinical trial designed to evaluate the safety and antiviral activity of the ApB DC vaccine, a therapeutic vaccine derived from autologous dendritic cells loaded with autologous HIV-1 infected apoptotic cells. The study will be conducted in three phases. The first is the pre-vaccination phase that includes study entry, isolation of autologous virus, and initiation of antiretroviral therapy. Once the patient's viral load has been suppressed to undetectable levels (<50 copies/mL) and sufficient virus has been isolated, the second phase will begin. This includes leukapheresis in order to harvest monocytes and lymphocytes necessary for vaccine preparation. Three vaccine doses will be administered subcutaneously every other week. Six weeks after the last vaccination, the third phase, analytic treatment interruption (ATI) phase, will begin. A fourth, booster dose of vaccine will be given two weeks after the start of treatment interruption. The treatment interruption will be continued for twelve weeks after which the primary HIV provider will decide whether or not antiretroviral therapy should be restarted. CD4 and viral load will be closely monitored throughout the study especially during treatment interruption. Follow-up will be continued for 24 weeks after the 12-week treatment interruption.
Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
HIV Infections
Biological: Autologous HIV-1 ApB DC Vaccine
Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption
Experimental: Autologous HIV-1 ApB DC Vaccine
Subjects who will receive ApB Dendritic cell vaccine
Intervention: Biological: Autologous HIV-1 ApB DC Vaccine

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
September 2012
September 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Confirmed HIV-1 infection.
  • CD4 greater than or equal to 350 cells/mL within 8 weeks prior to study entry.
  • Plasma HIV-1 RNA level of 5000-100,000 copies/mL within 8 weeks prior to study entry.
  • Antiretroviral therapy naive.
  • Willingness to interrupt ART for at least 12 weeks.
  • Written informed consent.

Exclusion Criteria:

  • Treatment within 30 days prior to study entry with systemic steroids or other immunosuppressives, or any underlying disease which may require use of such medications during the study period.
  • Receipt of any vaccinations other than routine ones within 6 months of study entry
  • Pregnancy or breastfeeding
  • Previous or current CDC Category C event
  • Receipt of any investigational product within 12 weeks prior to study entry.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Riddler 055794
5U19AI055794 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Sharon Riddler, University of Pittsburgh
Sharon Riddler
National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator: Sharon A Riddler, MD MPH University of Pittsburgh
University of Pittsburgh
May 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP